Shots:
- VivaVision has reported topline P-II trial data assessing 1.0% or 0.5% VVN461 (JAK1/TYK2 inhibitor) vs 1% prednisolone acetate (PA) for the treatment of non-infectious anterior uveitis in 86 Chinese pts for 28 days
- Trial demonstrated non-inferior efficacy to PA, achieving a 2-step ACC grade reduction (measured via SUN scale) as the 1EP & significant improvements in other EPs, with inflammation reduction seen as early as Day 3; data to be presented at future conferences
- Additionally, VivaVision has scheduled a discussion with Chinese CDE & intends to request a Type C meeting with the US FDA to discuss P-III trials
Ref: PRNewswire | Image: VivaVision Biotech
Related News:- Ipsen Reports P-II (ELMWOOD) Trial Data of Elafibranor for Primary Sclerosing Cholangitis (PSC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
